分化型甲状腺癌患者不明原因高甲状腺球蛋白血症可作为放射性碘辅助治疗指征:一项前瞻性多中心研究
该前瞻性多中心研究连续纳入5家三级医疗机构的254例全甲状腺切除后刺激状态下血清甲状腺球蛋白>10 ng/mL但无结构性疾病证据的分化型甲状腺癌患者,给予5.55 GBq 131I辅助治疗后评估反应。结果显示辅助治疗后超过80%患者达到非结构性或功能性不完全反应,作者认为不明原因高甲状腺球蛋白血症患者是放射性碘辅助治疗的明确候选者。
要点
- 全甲状腺切除后刺激状态下甲状腺球蛋白>10 ng/mL且无结构性疾病证据的患者被连续纳入研究。
- 给予5.55 GBq 131I后,88.6%患者被分层为中危,5.5%为高危,5.9%为低危。
核心结论
- 超过90%的不明原因高甲状腺球蛋白血症的全甲状腺切除分化型甲状腺癌患者被分层为中危至高危。
- 使用5.55 GBq 131I的放射性碘辅助治疗可揭示生化、功能或结构性疾病,并使超过80%患者达到非结构性或功能性不完全反应。
- 作者认为不明原因高甲状腺球蛋白血症的全甲状腺切除分化型甲状腺癌患者是放射性碘辅助治疗的明确候选者。
研究设计与样本
- 前瞻性多中心研究,连续纳入5家三级医疗机构的全甲状腺切除分化型甲状腺癌患者。
- 纳入标准为刺激状态下血清甲状腺球蛋白水平大于10 ng/mL但无结构性疾病证据。
- 共254例受试者纳入分析,中位刺激状态下甲状腺球蛋白水平为27.1 ng/mL。
- 给予5.55 GBq 131I后比较辅助治疗前后持续、复发或转移性分化型甲状腺癌风险。
- 辅助治疗后6至12个月探究高甲状腺球蛋白血症的原因并评估对辅助治疗的反应。
主要发现
- 辅助治疗后立即评估,低危、中危、高危分别占5.9%、88.6%、5.5%,与辅助治疗前风险分层无显著差异(P=0.952)。
- 中位随访10.6个月期间,高甲状腺球蛋白血症最终归因于甲状腺残留、生化疾病、结构或功能性疾病的比例分别为17.3%、54.3%、28.4%。
- 反应为极好、不确定、生化不完全、结构或功能不完全的患者分别占18.1%、27.2%、36.2%、18.5%。
- 高甲状腺球蛋白血症原因分布及对辅助治疗的反应在3个术后风险组间相当。
- 仅接受放射性碘辅助治疗的患者,抑制状态下甲状腺球蛋白水平随时间显著下降。
临床怎么用
- 作者认为不明原因高甲状腺球蛋白血症的全甲状腺切除分化型甲状腺癌患者是放射性碘辅助治疗的明确候选者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The management for totally thyroidectomized differentiated thyroid cancer (TT-DTC) patients with unexplained hyperthyroglobulinemia remains indeterminate because of evidence scarcity. This multicenter study aimed at prospectively evaluating the response to radioiodine (131I) adjuvant therapy (RAT) and its potential role in risk stratification and causal clarification. Methods: TT-DTC patients with stimulated serum thyroglobulin levels greater than 10 ng/mL but no structurally evident disease were consecutively enrolled in 5 tertiary-care institutions. After the administration of 5.55 GBq of 131I, the risk of persistent, recurrent, or metastatic differentiated thyroid cancer (prmDTC) was compared with that before RAT. The causes of hyperthyroglobulinemia were explored-and the response to RAT assessed-6-12 mo after RAT. The change in suppressed thyroglobulin level was reported. Results: A cohort of 254 subjects with a median stimulated thyroglobulin level of 27.1 ng/mL was enrolled for the analyses. Immediately after RAT, low, intermediate, and high risk were identified in 5.9%, 88.6%, and 5.5% patients, respectively, with no significant difference in risk stratification compared with that before RAT (P = 0.952). During the follow-up (median, 10.6 mo), hyperthyroglobulinemia was ultimately attributed to a thyroid remnant, biochemical disease, and structural or functional disease in 17.3%, 54.3%, and 28.4% of subjects, respectively. In addition, responses that were excellent, indeterminate, biochemically incomplete, and structurally or functionally incomplete were achieved in 18.1%, 27.2%, 36.2%, and 18.5% of patients, respectively. Notably, the distribution for either cause of hyperthyroglobulinemia or response to RAT was comparable among the 3 postoperative risk groups. Suppressed thyroglobulin levels in patients who merely received RAT declined significantly over time. Conclusion: Our study demonstrated that over 90% of TT-DTC patients with unexplained hyperthyroglobulinemia are stratified as being at intermediate to high risk, and RAT using 5.55 GBq of 131I reveals biochemical, functional, or structural disease and yields a non-structurally or -functionally incomplete response in more than 80% patients, suggesting that TT-DTC patients with unexplained hyperthyroglobulinemia are explicit candidates for RAT.
引用
- Cheng L, Sa R, Luo Q, et al. Unexplained Hyperthyroglobulinemia in Differentiated Thyroid Cancer Patients as an Indication for Radioiodine Adjuvant Therapy: A Prospective Multicenter Study. J Nucl Med. 2020. PMID: 32358095. doi:10.2967/jnumed.120.243642
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。